A retrospective single-centre evaluation of systemic anticancer therapy near the end of life in patients with solid organ malignancies
{{output}}
Background: Systemic anticancer therapy (SACT) near the end of life can contribute to significant patient morbidity and mortality in an already vulnerable population. There are variable rates of SACT use within 30 days of death i... ...
